logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Sonnet BioTherapeutics Holdings, Inc.

SONN

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010ā€¦ read more

Healthcare

Biotechnology

16 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.54

Price

-5.85%

-$0.22

$3.76

Previous Close

$3.68

Open

Premium

52w Discount
Market Cap

$22.175m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$1m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$13.286m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$12.83

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$662.260k

$3.836m

Assets

$3.174m

Liabilities

$90.450k

Debt
Debt to Assets

2.4%

-

Debt to EBITDA
Free Cash Flow

-$11.633m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.